Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection.
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Infiltrative Breast Cancer
Female
Infiltrative Breast Cancer
Trial Information
Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection.
Inclusion Criteria:
- patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy)
- approval and informed consent
Exclusion Criteria:
- chemotherapy
- locoregional radiotherapy
- prevalent axillary lymph node
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Determination of an optimized protocol for SLN identification, with a double method using isotope and methylene blue dye injection.
Principal Investigator
Jean-Pierre Bellocq, MD
Investigator Role:
Study Director
Investigator Affiliation:
Hôpitaux Universitaires de Strasbourg
Authority:
France: Ministry of Health
Study ID:
3157
NCT ID:
NCT00314405
Start Date:
April 2006
Completion Date:
Related Keywords:
- Infiltrative Breast Cancer
- sentinel lymph node
- SLN
- probe
- breast cancer
- lymphoscintigraphy
- methylene blue dye
- Breast Neoplasms
Name | Location |
|---|
